Fig. 3.

A prompt post-transplant increase in antibody levels against glycoprotein B is not explained by either low level or high level viraemia.

Total anti-gB antibody levels were measured by standard ELISA and are shown for individual patients. A-B) Patients were stratified for viraemia (red) versus non-viraemia (black) in vaccinated (A; n = 10) and placebo recipients (n = 4; B). C-D) Alternatively, vaccine (C) or placebo (D) patients were stratified by requirement for antiviral treatment (viraemia exceeding 3000 genome copies/ml) and are depicted in green: Serum samples were collected at the time of vaccination time of transplantation and on days: 7, 35, 63 and 90 post-transplant. Dashed line represents the cut off and was informed by control sera taken from healthy seronegative individuals (n = 6). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)